Page last updated: 2024-10-17

citric acid, anhydrous and Kidney Failure, Chronic

citric acid, anhydrous has been researched along with Kidney Failure, Chronic in 85 studies

Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.

Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.

Research Excerpts

ExcerptRelevanceReference
"Taurolidine-citrate use did not decrease all-cause bacteremia and was associated with a greater need for thrombolytic treatment."9.14A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. ( Al-Sayed, T; Bhat, R; Cheesbrough, JS; Curry, A; Diggle, P; Ebah, L; Heap, M; Millband, N; Mitra, S; Saxena, R; Schulz, M; Solomon, LR; Waterhouse, D, 2010)
"Taurolidine-citrate use did not decrease all-cause bacteremia and was associated with a greater need for thrombolytic treatment."5.14A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. ( Al-Sayed, T; Bhat, R; Cheesbrough, JS; Curry, A; Diggle, P; Ebah, L; Heap, M; Millband, N; Mitra, S; Saxena, R; Schulz, M; Solomon, LR; Waterhouse, D, 2010)
" The objective was to establish the equivalence of iron delivery via dialysate and IV infusion using a pharmacokinetic approach."3.11Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate. ( Marbury, T; Pratt, RD; van der Horst, E; van Heuveln, F, 2022)
"SLED under regional citrate anticoagulation is safe and effective."2.78[The safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis]. ( Chen, ZW; Fu, P; Liao, YJ; Tang, Y; Wang, TL; Yang, YY; Zhang, L; Zhao, YL, 2013)
" Patients were randomly divided into two groups: group A (Mg group), in which patients were given magnesium citrate orally at a dosage of 610 mg every other day for 2 months and group B (control group), in which patients received only calcium acetate therapy as a phosphate binder."2.73Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. ( Akcay, A; Covic, A; Kanbay, M; Metin, MR; Turgut, F; Uz, E, 2008)
"Thirty end-stage renal disease (ESRD) patients with subclavian or jugular single lumen catheters as temporary vascular access for hemodialysis were enrolled."2.69Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. ( Boh, M; Buturović, J; Ivanovich, P; Kandus, A; Klinkmann, J; Ponikvar, R, 1998)
" To determine whether calcium acetate (Ca acetate) also augments Al absorption, 10 normal volunteers were each given orally, three-day courses of the following drug combinations dosed four times daily: 1) aluminum hydroxide gel (Al[OH]3) (5 ml) alone; 2) Al[OH]3 (5 ml) plus Ca acetate (1330 mg); 3) Al[OH]3 (5 ml) plus Ca citr (950 mg)."2.67Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. ( Butzin, CA; Califano, JR; Nolan, CR, 1990)
"Hypocitraturia and hypercalciuria are risk factors for calcium stone disease."2.47Diet-induced metabolic acidosis. ( Adeva, MM; Souto, G, 2011)
"During critical illness, regional anticoagulation with citrate for CRRT seems superior to heparin anticoagulation concerning tolerance and safety, mainly due to less bleeding."2.46Citrate anticoagulation for continuous renal replacement therapy in the critically ill. ( Oudemans-van Straaten, HM, 2010)
"Using predictive Q(Ca) dosing and integrating control of the infusion pumps with the dialysis machine, SLED-RCA can be near-automated today to provide a user-friendly and safe system."2.46Automated regional citrate anticoagulation: technological barriers and possible solutions. ( Frinak, S; Szamosfalvi, B; Yee, J, 2010)
"The cost of end-stage renal disease (ESRD) care, survival data, and patient utilities were estimated from published sources."2.41To reuse or not to reuse? An economic evaluation of hemodialyzer reuse versus conventional single-use hemodialysis for chronic hemodialysis patients. ( Donaldson, C; Manns, BJ; Richardson, RM; Taub, K, 2002)
" During the maintenance phase (period of epoetin therapy after correction of iron deficiency), the use of low-dose intravenous iron supplementation (10 to 20 mg per haemodialysis treatment or 100 mg every second week) avoids iron overtreatment and minimises potential adverse effects."2.40Safety aspects of parenteral iron in patients with end-stage renal disease. ( Hörl, WH; Sunder-Plassmann, G, 1997)
" We conclude that long-term administration of alkali citrate is beneficial in patients with PH."2.38Management of primary hyperoxaluria: efficacy of oral citrate administration. ( Hoppe, B; Leumann, E; Neuhaus, T, 1993)
" Citrate was dosed at median 2."1.51Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. ( Chua, HR; Haroon, SWP; Lau, T; Lee, N; Mukhopadhyay, A; Murali, TM; Phua, J; Tan, JN; Tan, ZY, 2019)
"Stone formation and nephrocalcinosis are both very common features of primary hyperoxaluria, yet the extent of each disease varies markedly between patients."1.42Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. ( Bergstralh, EJ; Lieske, JC; Mehta, RA; Milliner, DS; Tang, X; Vrtiska, TJ, 2015)
"The primary hyperoxalurias are autosomal recessive disorders resulting from deficiency of hepatic alanine:glyoxylate aminotransferase (PHI) or D-glycerate dehydrogenase/glyoxylate reductase (PHII)."1.31Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. ( Milliner, DS; Smith, LH; Wilson, DM, 2001)
" The permeability of the filtering membrane to phosphorus decreased in accordance with the dosage of sodium ferrous citrate and dessicated aluminum hydroxide."1.29Effect of iron as a new type of phosphate binder in hemodialysis patients. ( Fujimori, H; Hasegawa, K; Kasai, M; Komori, M; Kuroda, M; Kuroda, S; Maejima, K; Nagamatsu, K; Ninomiya, R; Samejima, M, 1995)
"Both SS-patients with and without known distal renal tubular acidosis (dRTA) were included, dRTA was found in 18/27 (67%), impaired urine concentrating ability in 13/27 (48%)."1.29Biochemical markers of renal disease in primary Sjögren's syndrome. ( Denneberg, T; Eriksson, P; Larsson, L; Lindström, F, 1995)
"Two patients with lactic acidosis are described, along with our experience using CAVHD and citrate in other clinical settings."1.28Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation. ( Galishoff, M; Kirschbaum, B; Reines, HD, 1992)
"Following the occurrence of aluminum encephalopathy in four patients with chronic renal failure, we studied 34 azotemic patients seen during the same year and five volunteers who took varying combinations of aluminum hydroxide and an alkalinizing citrate (Shohl's) solution."1.28Hyperaluminemia in renal failure: the influence of age and citrate intake. ( Ahmed, S; Bakir, AA; Dunea, G; Hessl, SM; Hryhorczuk, DO; Levy, PS; Spengler, R, 1989)
"A 66 year-old man with chronic renal failure developed hypercalcaemia during acetolyte medication."1.27[Transient extra-osseous increase of isotope activity in the bone scintigram in acetolyt-induced hypercalcemia]. ( Biesenbach, G; Dienstl, E; Grafinger, P; Kaiser, W; Stuby, U; Zazgornik, J, 1988)

Research

Studies (85)

TimeframeStudies, this research(%)All Research%
pre-199014 (16.47)18.7374
1990's20 (23.53)18.2507
2000's10 (11.76)29.6817
2010's35 (41.18)24.3611
2020's6 (7.06)2.80

Authors

AuthorsStudies
Marbury, T1
van Heuveln, F1
van der Horst, E1
Pratt, RD1
Bargnoux, AS1
Barguil, Y1
Zaoui, E1
Jean, G1
Cristol, JP2
Poh, CB1
Tan, PC1
Kam, JW1
Siau, C1
Lim, NL1
Yeon, W1
Cui, HH1
Ding, HT1
Song, XY1
Yan, P1
Chea, KL1
Liu, JS1
Chionh, CY1
Potier, J1
Dolley-Hitze, T1
Hamel, D1
Landru, I1
Cardineau, E1
Queffeulou, G1
Zagdoun, E1
Renaudineau, E1
Molinari, N1
Gamon, L1
Morena, M1
Canaud, B2
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z4
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J3
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T3
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C3
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X3
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB2
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y3
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L2
Wang, L4
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z3
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P3
Atyah, M1
Ma, Q2
Xu, Y2
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L5
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X4
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y3
Huang, M1
Zhu, Y2
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y2
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S4
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y2
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Neri, L1
Bellocchio, F1
Kircelli, F1
Jirka, T1
Levannier, M1
Guillaume, J1
Attaf, D2
Barbieri, C1
Garbelli, M1
Stuard, S1
Chazot, C1
Couchoud, C1
Hannedouche, T1
Bauwens, M1
Ecochard, R1
Lassalle, M1
Frimat, L1
Choukroun, G1
Lobbedez, T1
Khoo, BZE1
Lim, RS1
See, YP1
Yeo, SC1
Lin, Y1
Duan, Z2
Jia, L2
Gui, B2
Tan, JN1
Haroon, SWP1
Mukhopadhyay, A1
Lau, T1
Murali, TM1
Phua, J1
Tan, ZY1
Lee, N1
Chua, HR1
Sanai, T1
Ono, T1
Fukumitsu, T1
Kosmadakis, G1
Correia, EDC1
Albaret, J1
Somda, F1
Aguilera, D1
Skagerlind, MSE1
Stegmayr, BG1
Yao, Z1
Ma, W1
Sun, XY1
Jia, S1
Durand, PY1
Nicco, C1
Serteyn, D1
Edeas, M1
Kruse, A2
Uehlinger, DE1
Eisenberger, U1
Wang, TL1
Zhao, YL1
Chen, ZW1
Yang, YY1
Liao, YJ1
Raimundo, M1
Crichton, S1
Lei, K1
Sanderson, B1
Smith, J1
Brooks, J1
Ng, J1
Lemmich Smith, J1
McKenzie, C1
Beale, R1
Dickie, H1
Ostermann, M1
Rocha, AD1
Padua, VC1
Oliveira, E1
Guimaraes, MM1
Lugon, JR1
Strogoff de Matos, JP1
Panichi, V1
Fiaccadori, E1
Rosati, A1
Fanelli, R1
Bernabini, G1
Scatena, A1
Pizzarelli, F1
Fontseré, N1
Cardozo, C1
Donate, J1
Soriano, A1
Muros, M1
Pons, M1
Mensa, J1
Campistol, JM1
Navarro-González, JF1
Maduell, F1
François, K1
Wissing, KM1
Jacobs, R1
Boone, D1
Jacobs, K1
Tielemans, C1
Tang, X1
Bergstralh, EJ1
Mehta, RA1
Vrtiska, TJ1
Milliner, DS2
Lieske, JC1
Bakir, AA3
Yao, G1
Zhu, D1
Fu, R1
Ge, H1
Tian, L1
Schmitz, M1
Loke, O1
Fach, B1
Kalb, K1
Heering, PJ1
Meinke, D1
Rawer, P1
Galle, J1
Kozik-Jaromin, J1
Turgut, F1
Kanbay, M1
Metin, MR1
Uz, E1
Akcay, A1
Covic, A1
Forni, LG1
Humes, HD1
Sobota, JT1
Ding, F1
Song, JH1
Oudemans-van Straaten, HM1
Thijssen, S1
Raimann, J1
Bhalani, V1
Levin, NW1
Kotanko, P2
Szamosfalvi, B1
Frinak, S1
Yee, J1
Solomon, LR1
Cheesbrough, JS1
Ebah, L1
Al-Sayed, T1
Heap, M1
Millband, N1
Waterhouse, D1
Mitra, S1
Curry, A1
Saxena, R1
Bhat, R1
Schulz, M1
Diggle, P1
Kreuzer, M1
Ahlenstiel, T1
Kanzelmeyer, N1
Ehrich, JH1
Pape, L1
Cheng, YL1
Yu, AW1
Tsang, KY1
Shah, DH1
Kjellstrand, CM1
Wong, SM1
Lau, WY1
Hau, LM1
Ing, TS1
Wright, S1
Steinwandel, U1
Ferrari, P1
Filiopoulos, V1
Hadjiyannakos, D1
Koutis, I1
Trompouki, S1
Micha, T1
Lazarou, D1
Vlassopoulos, D1
Adeva, MM1
Souto, G1
Chen, C1
Ye, C1
Parikh, S1
Nijmeh, R1
Van Cleef, S1
Timmerman, S1
Bhatt, UY1
Agarwal, AK1
Sands, JJ1
Segal, JH1
Ho, CH1
Usvat, L1
Young, A1
Carter, M1
Sergeyeva, O1
Korth, L1
Maunsell, E1
Krishnan, M1
Diaz-Buxo, JA1
Zatelli, A1
Pierantozzi, M1
D'Ippolito, P1
Bigliati, M1
Zini, E1
Ogawa, Y2
Machida, N2
Jahana, M1
Gakiya, M1
Chinen, Y2
Oda, M2
Morozumi, M2
Sugaya, K2
Stapenhorst, L1
Sassen, R1
Beck, B1
Laube, N1
Hesse, A1
Hoppe, B2
Ogawa, T1
Hokama, S1
Uchida, A1
Motoyoshi, Y1
Hattori, M1
Seaton, RD1
Duncan, KA1
Pinnick, RV1
Diederich, DA2
Wiegmann, TB2
Yamakawa, M1
Yamamoto, T1
Kishimoto, T1
Mizutani, Y1
Yatsuboshi, M1
Nishitani, H1
Hirata, S1
Horiuchi, N1
Maekawa, M1
Kuroda, S1
Komori, M1
Nagamatsu, K1
Ninomiya, R1
Maejima, K1
Hasegawa, K1
Samejima, M1
Kuroda, M1
Fujimori, H1
Kasai, M1
Nestel, AW1
Meyers, AM1
Paiker, J1
Rollin, HB1
Lindberg, JS2
Copley, JB3
Koenig, KG1
Cushner, HM2
Janssen, MJ1
Huijgens, PC1
Bouman, AA1
Oe, PL1
Donker, AJ1
van der Meulen, J1
Sakhaee, K1
Wabner, CL1
Zerwekh, JE1
Pak, L1
Poindexter, JR1
Pak, CY1
Leumann, E1
Neuhaus, T1
Hirano, T1
Otake, H1
Ichikawa, K1
Ohmori, Y1
Kunitomo, K1
Nomura, S1
Watanabe, Y1
Otsuka, N1
Osawa, G1
Eriksson, P1
Denneberg, T1
Larsson, L1
Lindström, F1
Sunder-Plassmann, G1
Hörl, WH1
Buturović, J1
Ponikvar, R1
Kandus, A1
Boh, M1
Klinkmann, J1
Ivanovich, P1
Palsson, R1
Niles, JL1
Künstle, T1
Maulhardt, S1
Grünberger, M1
Rothe, KF1
Wilson, DM1
Smith, LH1
Sodemann, K1
Polaschegg, HD1
Feldmer, B1
Nunn, JH1
Ng, SK1
Sharkey, I1
Coulthard, M1
Manns, BJ1
Taub, K1
Richardson, RM1
Donaldson, C1
Kirschbaum, B1
Galishoff, M1
Reines, HD1
Rudy, D1
Sica, DA1
Comstock, T1
Davis, J1
Savory, J1
Schoolwerth, AC2
Kanagawa, S1
Yosikawa, Y1
Dohi, Y1
Saha, H1
Pietilä, K1
Mustonen, J1
Pasternack, A1
Mörsky, P1
Seppälä, E1
Reinikainen, P1
Wasan, SM1
Godley, PJ1
Dorhout Mees, EJ1
Basçi, A1
Nolan, CR1
Califano, JR1
Butzin, CA1
Brown, SJ1
Slizofski, WJ1
Dadparvar, S1
Caruana, RJ1
Weinstein, RS1
Campbell, HT1
Chaudhary, BA1
Smith, KL1
Kurunsaari, KM1
Kirschbaum, BB1
Sheikh, MS1
Maguire, JA1
Emmett, M1
Santa Ana, CA1
Nicar, MJ1
Schiller, LR1
Fordtran, JS1
Hryhorczuk, DO1
Ahmed, S1
Hessl, SM1
Levy, PS1
Spengler, R1
Dunea, G1
MacDougall, ML1
Biesenbach, G1
Grafinger, P1
Kaiser, W1
Stuby, U1
Dienstl, E1
Zazgornik, J1
Nordal, KP1
Dahl, E1
Sørhus, K1
Berg, KJ1
Thomassen, Y1
Kofstad, J1
Halse, J1
Foulks, CJ1
Schulz, W1
Deuber, HJ1
Santos, F1
Massie, MD1
Chan, JC1
Kelleher, SP1
Schulman, G1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients[NCT04353674]40 participants (Anticipated)Interventional2020-04-28Recruiting
Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440]30 participants (Anticipated)Observational2019-06-01Active, not recruiting
Prospective, Randomized, Controlled Trial Evaluating the Efficacy of a Lock-therapy With a Solution of Taurolidine/Citrate (TauroLock) vs Standard Saline Solution for the Primary Prevention of Catheter-related Infections (CLI) in Adult Patients Wtih a Non[NCT02279121]162 participants (Actual)Interventional2014-11-30Completed
A Prospective Study of Citrate Based Dialysate in Pediatric Patients Receiving Intermittent Hemodialysis[NCT01590550]18 participants (Actual)Observational2012-05-31Completed
Alkaline Diet for Insulin Sensitivity[NCT02501343]32 participants (Actual)Interventional2015-03-31Completed
Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration[NCT00583765]20 participants (Actual)Observational2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Dialyzer Clotting Rate

Dialyzer clotting rate will be assessed as the percent of hemodialysis treatments that developed a clot in the dialyzer from the time that the patient is enrolled in the study until the time hemodialysis treatments with Citrasate® are discontinued. (NCT01590550)
Timeframe: Followed until HD with Citrate dialysate is discontinued, average 3 weeks

Interventionpercentage of total treatments (Number)
Observational6

Heparin Use Rate

The heparin use rate will be assessed as the percentage of hemodialysis treatments that required additional use of heparin to maintain circuit patency. This will be assessed from the time that the patient is enrolled in the study until the time hemodialysis treatments with Citrasate® are discontinued based on clinical indications, upto a maximum period of 6 months (NCT01590550)
Timeframe: Patients will be followed until inpatient hemodialysis sessions with Citrasate® are discontinued

Interventionpercentage of hemodialysis treatments (Number)
Observational0

Saline Flush Rate

Saline flush rate will be assesed as the percentage of hemodialysis treatments that require one or more saline flushes to maintain circuit patency from the time that the patient is enrolled in the study until the time hemodialysis treatments with Citrasate® are discontinued based on clinical indications, upto a maximum period of 6 months (NCT01590550)
Timeframe: Patients will be followed until HD Citrate dialysate is discontinued, average 3 weeks

Interventionpercentage of hemodialysis treatments (Number)
Observational0

Reviews

10 reviews available for citric acid, anhydrous and Kidney Failure, Chronic

ArticleYear
[Dialysis monitoring: peritoneal equilibrium test, regional citrate anticoagulation and residual renal function].
    Annales de biologie clinique, 2019, 08-01, Volume: 77, Issue:4

    Topics: Anticoagulants; Calcium; Citric Acid; Humans; Kidney; Kidney Failure, Chronic; Kidney Function Tests

2019
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Citrate anticoagulation for continuous renal replacement therapy in the critically ill.
    Blood purification, 2010, Volume: 29, Issue:2

    Topics: Acid-Base Imbalance; Aged; Anticoagulants; Buffers; Citric Acid; Citric Acid Cycle; Clinical Protoco

2010
Automated regional citrate anticoagulation: technological barriers and possible solutions.
    Blood purification, 2010, Volume: 29, Issue:2

    Topics: Anticoagulants; Automation; Bicarbonates; Calcium; Chelating Agents; Citric Acid; Equipment Design;

2010
Diet-induced metabolic acidosis.
    Clinical nutrition (Edinburgh, Scotland), 2011, Volume: 30, Issue:4

    Topics: Acid-Base Equilibrium; Acidosis; Bicarbonates; Biomarkers; Cardiovascular Diseases; Citric Acid; Die

2011
Management of primary hyperoxaluria: efficacy of oral citrate administration.
    Pediatric nephrology (Berlin, Germany), 1993, Volume: 7, Issue:2

    Topics: Administration, Oral; Adolescent; Calcium Oxalate; Child; Citrates; Citric Acid; Female; Humans; Hyp

1993
Safety aspects of parenteral iron in patients with end-stage renal disease.
    Drug safety, 1997, Volume: 17, Issue:4

    Topics: Anemia, Iron-Deficiency; Citric Acid; Drug Combinations; Drug Monitoring; Erythropoietin; Ferric Com

1997
To reuse or not to reuse? An economic evaluation of hemodialyzer reuse versus conventional single-use hemodialysis for chronic hemodialysis patients.
    International journal of technology assessment in health care, 2002,Winter, Volume: 18, Issue:1

    Topics: Canada; Citric Acid; Decision Support Techniques; Equipment Reuse; Female; Formaldehyde; Health Care

2002
Phosphate binders in hyperphosphatemia of chronic renal failure.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:9

    Topics: Aluminum Hydroxide; Calcium Carbonate; Citrates; Citric Acid; Glomerular Filtration Rate; Humans; Ki

1991
Risk factors in aluminum toxicity in children with chronic renal failure.
    Nephron, 1986, Volume: 42, Issue:3

    Topics: Acidosis; Adolescent; Adult; Aluminum; Aluminum Hydroxide; Bone and Bones; Child; Citrates; Citric A

1986

Trials

23 trials available for citric acid, anhydrous and Kidney Failure, Chronic

ArticleYear
Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:5

    Topics: Administration, Intravenous; Citric Acid; Cross-Over Studies; Dialysis Solutions; Diphosphates; Hema

2022
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:3

    Topics: Aged; Anticoagulants; Blood Coagulation; Case-Control Studies; Citric Acid; Drug Liberation; Female;

2018
Microbiota Quality and Mitochondrial Activity Link with Occurrence of Muscle Cramps in Hemodialysis Patients using Citrate Dialysate: A Pilot Study.
    Blood purification, 2018, Volume: 46, Issue:4

    Topics: Aged; Aged, 80 and over; Bacteria; Citric Acid; Dysbiosis; Female; Gastrointestinal Microbiome; Huma

2018
Arterial stiffness depends on serum ionized calcium levels during dialysis with regional citrate anticoagulation.
    Artificial organs, 2013, Volume: 37, Issue:5

    Topics: Adult; Aged; Anticoagulants; Biomarkers; Calcium; Citric Acid; Cross-Over Studies; Female; Germany;

2013
[The safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis].
    Zhonghua nei ke za zhi, 2013, Volume: 52, Issue:6

    Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Citric Acid; Female; Humans; Kidney Failure, Chron

2013
Effects of citrate-enriched bicarbonate based dialysate on anticoagulation and dialyzer reuse in maintenance hemodialysis patients.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2014, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Bicarbonates; Blood Coagulation; Citric Acid; Cross-Over Studies; Di

2014
Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients.
    TheScientificWorldJournal, 2013, Volume: 2013

    Topics: Adult; Aged; Anticoagulants; Citric Acid; Dialysis Solutions; Feasibility Studies; Female; Hemodiafi

2013
[Evaluation of the application of regional citrate anticoagulation in sustained low efficiency hemodialysis].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:12

    Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citrates; Citric Acid; Dialysis Solutions; F

2014
Effects of citrate dialysate in chronic dialysis: a multicentre randomized crossover study.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:8

    Topics: Adult; Aged; Calcium Chelating Agents; Citric Acid; Cross-Over Studies; Dialysis Solutions; Female;

2016
Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis.
    International urology and nephrology, 2008, Volume: 40, Issue:4

    Topics: Adult; Calcium; Carotid Arteries; Citric Acid; Female; Humans; Kidney Failure, Chronic; Male; Middle

2008
A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure.
    Blood purification, 2010, Volume: 29, Issue:2

    Topics: Acute Kidney Injury; Anticoagulants; Antigen-Presenting Cells; Atherosclerosis; Cardiovascular Disea

2010
A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 55, Issue:6

    Topics: Adult; Aged; Anti-Infective Agents; Anticoagulants; Bacteremia; Catheters, Indwelling; Citric Acid;

2010
Anticoagulation during haemodialysis using a citrate-enriched dialysate: a feasibility study.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:2

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Citric Acid; Cross-Over Studies; Dialysis Solutions;

2011
Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial.
    American journal of nephrology, 2011, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anticoagulants; Catheter-Related Infections;

2011
Effects of citrate acid concentrate (citrasate®) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial.
    Blood purification, 2012, Volume: 33, Issue:1-3

    Topics: Aged; Anticoagulants; Citric Acid; Dialysis Solutions; Female; Heparin; Humans; Kidney Failure, Chro

2012
Serum levels of acetate and TCA cycle intermediates during hemodialysis in relation to symptoms.
    Nephron, 1982, Volume: 32, Issue:2

    Topics: Acetates; Adult; Citrates; Citric Acid; Citric Acid Cycle; Female; Humans; Isocitrates; Ketoglutaric

1982
Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients.
    Nephron, 1994, Volume: 68, Issue:2

    Topics: Adult; Aged; Aluminum; Calcium, Dietary; Citrates; Citric Acid; Contraindications; Female; Humans; K

1994
Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study.
    Artificial organs, 1998, Volume: 22, Issue:11

    Topics: Aged; Anticoagulants; Catheterization, Central Venous; Citric Acid; Female; Heparin; Humans; Kidney

1998
Influence of calcium acetate or calcium citrate on intestinal aluminum absorption.
    Kidney international, 1990, Volume: 38, Issue:5

    Topics: Acetates; Acetic Acid; Adult; Aluminum; Aluminum Hydroxide; Citrates; Citric Acid; Contraindications

1990
Long-term comparisons of citrate and heparin as anticoagulants for hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1987, Volume: 9, Issue:5

    Topics: Anticoagulants; Citrates; Citric Acid; Clinical Trials as Topic; Heparin; Humans; Infusion Pumps; Ki

1987
Gastrointestinal absorption and urinary excretion of aluminium in patients with predialysis chronic renal failure.
    Pharmacology & toxicology, 1988, Volume: 63, Issue:5

    Topics: Adult; Aged; Aluminum; Calcium; Citrates; Citric Acid; Creatinine; Digestive System; Female; Humans;

1988
Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF.
    Kidney international, 1988, Volume: 33, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Aluminum; Calcium; Citrates; Citric Acid; Clinical Trials as Topi

1988

Other Studies

53 other studies available for citric acid, anhydrous and Kidney Failure, Chronic

ArticleYear
Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy - A Safe and Effective Low-Dose Protocol.
    Nephrology (Carlton, Vic.), 2020, Volume: 25, Issue:4

    Topics: Aged; Anticoagulants; Blood Coagulation; Citric Acid; Continuous Renal Replacement Therapy; Female;

2020
Long-term effects of citric acid-based bicarbonate haemodialysis on patient outcomes: a survival propensity score-matched study in western France.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 07-01, Volume: 35, Issue:7

    Topics: Aged; Bicarbonates; Buffers; Calcium Chelating Agents; Citric Acid; Female; France; Humans; Kidney F

2020
Long-term mortality risk associated with citric acid- and acetic acid-based bicarbonate haemodialysis: a historical cohort propensity score-matched study in a large, multicentre, population-based study.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 07-01, Volume: 35, Issue:7

    Topics: Acetic Acid; Aged; Anti-Bacterial Agents; Bicarbonates; Buffers; Calcium Chelating Agents; Citric Ac

2020
Impact of the dialysate acid component on haemodialysis mortality rates.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 07-01, Volume: 35, Issue:7

    Topics: Acetic Acid; Aged; Anti-Bacterial Agents; Bicarbonates; Buffers; Calcium Chelating Agents; Citric Ac

2020
Dialysis circuit clotting in critically ill patients with COVID-19 infection.
    BMC nephrology, 2021, 04-20, Volume: 22, Issue:1

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Case-Control Studies; Citric Acid; Cohort Studies; Contin

2021
Citrate attenuates vascular calcification in chronic renal failure rats.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2017, Volume: 125, Issue:5

    Topics: Animals; Aorta; Calcium Chelating Agents; Citric Acid; Disease Models, Animal; Histocytochemistry; K

2017
Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy.
    Journal of intensive care medicine, 2019, Volume: 34, Issue:5

    Topics: Acute Kidney Injury; Aged; Anticoagulants; APACHE; Citric Acid; Drug Tolerance; Female; Humans; Hype

2019
Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis.
    Internal medicine (Tokyo, Japan), 2017, Sep-15, Volume: 56, Issue:18

    Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Citric Acid; Erythropoietin; Female; F

2017
Comparison of the hemodynamic tolerance and the biological parameters of four acetate-free hemodialysis methods.
    Nephrologie & therapeutique, 2017, Volume: 13, Issue:7

    Topics: Acetates; Aged; Aged, 80 and over; Citric Acid; Cross-Over Studies; Dialysis Solutions; Female; Hemo

2017
Magnesium Citrate Protects Against Vascular Calcification in an Adenine-induced Chronic Renal Failure Rat Model.
    Journal of cardiovascular pharmacology, 2018, Volume: 72, Issue:6

    Topics: Actins; Adenine; Alkaline Phosphatase; Animals; Aorta; Aortic Diseases; Calcium; Cardiovascular Agen

2018
Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels.
    Nephron. Clinical practice, 2013, Volume: 124, Issue:1-2

    Topics: Aged; Anticoagulants; Calcium; Citric Acid; Female; Humans; Ions; Kidney Failure, Chronic; Male; Par

2013
Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anticoagulants; C-Reactive Protein; Catheter-

2014
Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study.
    BMC nephrology, 2014, Jul-03, Volume: 15

    Topics: Acrylic Resins; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Citric Acid; Cohort Stud

2014
Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria.
    Kidney international, 2015, Volume: 87, Issue:3

    Topics: Adolescent; Adult; Age of Onset; Child; Child, Preschool; Citric Acid; Female; Humans; Hyperoxaluria

2015
The fatal interplay of aluminum and citrate in chronic renal failure: a lesson from three decades ago.
    Artificial organs, 2015, Volume: 39, Issue:2

    Topics: Aluminum; Aluminum Hydroxide; Antacids; Citric Acid; History, 19th Century; History, 20th Century; H

2015
Citrate Attenuates Adenine-Induced Chronic Renal Failure in Rats by Modulating the Th17/Treg Cell Balance.
    Inflammation, 2016, Volume: 39, Issue:1

    Topics: Adenine; Animals; Anti-Inflammatory Agents; Blood Urea Nitrogen; Cell Survival; Citric Acid; Creatin

2016
Recently published papers: Heavyweight problems in the intensive care unit?
    Critical care (London, England), 2008, Volume: 12, Issue:6

    Topics: Citric Acid; Humans; Intensive Care Units; Kidney Failure, Chronic; Obesity; Publishing

2008
A mathematical model of regional citrate anticoagulation in hemodialysis.
    Blood purification, 2010, Volume: 29, Issue:2

    Topics: Aged; Anticoagulants; Blood Proteins; Calcium; Chelating Agents; Citric Acid; Computer Simulation; F

2010
Management of regional citrate anticoagulation in pediatric high-flux dialysis: activated coagulation time versus post-filter ionized calcium.
    Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:7

    Topics: Adolescent; Anticoagulants; Blood Coagulation; Calcium; Child; Child, Preschool; Citric Acid; Drug M

2010
Citrate anticoagulation using ACD solution A during long-term haemodialysis.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:4

    Topics: Aged; Analysis of Variance; Anticoagulants; Bicarbonates; Biomarkers; Blood Coagulation; Calcium; Ci

2011
Regional anticoagulation with citrate for maintenance haemodialysis in a patient with liver cirrhosis for 30 months.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:8

    Topics: Anticoagulants; Blood Coagulation; Citric Acid; Glucose; Hemodialysis Solutions; Humans; Kidney Fail

2011
Catheter outcomes in the short-term inpatient setting: a controlled quality improvement study comparing citrate and heparin lock.
    Seminars in dialysis, 2012, Volume: 25, Issue:3

    Topics: Anticoagulants; Catheter-Related Infections; Catheters, Indwelling; Citric Acid; Female; Follow-Up S

2012
Effect of dietary supplements in reducing probability of death for uremic crises in dogs affected by chronic kidney disease (masked RCCT).
    TheScientificWorldJournal, 2012, Volume: 2012

    Topics: Animals; Calcium Carbonate; Chi-Square Distribution; Chitosan; Citric Acid; Creatinine; Dietary Supp

2012
Major factors modulating the serum oxalic acid level in hemodialysis patients.
    Frontiers in bioscience : a journal and virtual library, 2004, Sep-01, Volume: 9

    Topics: Aged; Ascorbic Acid; Citric Acid; Creatinine; Female; Glycolates; Humans; Kidney Failure, Chronic; M

2004
Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation.
    Pediatric nephrology (Berlin, Germany), 2005, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Calcineurin Inhibitors; Calcium Oxalate; Child; Citric Acid; Cyclosporine; Female

2005
Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria.
    Urological research, 2006, Volume: 34, Issue:1

    Topics: Aged; Calcium; Calcium Oxalate; Citric Acid; Female; Humans; Hyperoxaluria, Primary; Kidney Failure,

2006
Regional citrate anticoagulation in chronic hemodialysis patients.
    Transactions - American Society for Artificial Internal Organs, 1983, Volume: 29

    Topics: Anticoagulants; Blood Gas Analysis; Calcium; Citrates; Citric Acid; Heparin; Humans; Kidney Failure,

1983
Effect of iron as a new type of phosphate binder in hemodialysis patients.
    Nihon Jinzo Gakkai shi, 1995, Volume: 37, Issue:8

    Topics: Administration, Oral; Adult; Aged; Citric Acid; Female; Ferritins; Ferrous Compounds; Humans; Iron;

1995
Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study.
    Southern medical journal, 1993, Volume: 86, Issue:12

    Topics: Adult; Aged; Aluminum; Antacids; Citrates; Citric Acid; Female; Humans; Kidney Failure, Chronic; Mal

1993
Citrate versus heparin anticoagulation in chronic haemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1993, Volume: 8, Issue:11

    Topics: Aged; Blood Coagulation; Calcium; Citrates; Citric Acid; Creatinine; Female; Heparin; Humans; Kidney

1993
Calcium citrate without aluminum antacids does not cause aluminum retention in patients with functioning kidneys.
    Bone and mineral, 1993, Volume: 20, Issue:1

    Topics: Absorption; Adult; Aged; Aged, 80 and over; Aluminum; Antacids; Bone and Bones; Citrates; Citric Aci

1993
Metastatic calcification. Difference of uptake between Tc-99m HMDP and Ga-67 citrate.
    Clinical nuclear medicine, 1995, Volume: 20, Issue:9

    Topics: Bone and Bones; Calcinosis; Citrates; Citric Acid; Gallium Radioisotopes; Humans; Hypercalcemia; Kid

1995
Gallium 67 scintigraphy as a predictor of renal prognosis in primary immunoglobulin A nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1996, Volume: 27, Issue:2

    Topics: Adult; Case-Control Studies; Citrates; Citric Acid; Evaluation Studies as Topic; Female; Follow-Up S

1996
Biochemical markers of renal disease in primary Sjögren's syndrome.
    Scandinavian journal of urology and nephrology, 1995, Volume: 29, Issue:4

    Topics: Acetylglucosaminidase; Acidosis, Renal Tubular; Adult; Aged; Biopsy; Blood Flow Velocity; Citrates;

1995
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
    Kidney international, 1999, Volume: 55, Issue:5

    Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure

1999
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
    Kidney international, 1999, Volume: 55, Issue:5

    Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure

1999
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
    Kidney international, 1999, Volume: 55, Issue:5

    Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure

1999
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
    Kidney international, 1999, Volume: 55, Issue:5

    Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure

1999
[Heparin-induced thrombocytopenia and hemofiltration: regional anticoagulation with sodium citrate].
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2000, Volume: 35, Issue:2

    Topics: Anticoagulants; Citric Acid; Extracorporeal Circulation; Hemofiltration; Heparin; Humans; Kidney Fai

2000
Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.
    Kidney international, 2001, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Calcium; Calcium Oxalate; Child; Child, Preschool; Citric Acid; Crystallization;

2001
Two years' experience with Dialock and CLS (a new antimicrobial lock solution).
    Blood purification, 2001, Volume: 19, Issue:2

    Topics: Adult; Anti-Infective Agents; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling

2001
The dental implications of chronic use of acidic medicines in medically compromised children.
    Pharmacy world & science : PWS, 2001, Volume: 23, Issue:3

    Topics: Acids; Administration, Oral; Child; Citric Acid; Humans; Hydrogen-Ion Concentration; Kidney Failure,

2001
Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation.
    Critical care medicine, 1992, Volume: 20, Issue:3

    Topics: Acidosis, Lactic; Adult; Aged; Bicarbonates; Chlorides; Citrates; Citric Acid; Female; Hemofiltratio

1992
Aluminum-citrate interaction in end-stage renal disease.
    The International journal of artificial organs, 1991, Volume: 14, Issue:10

    Topics: Adult; Aluminum; Aluminum Hydroxide; Citrates; Citric Acid; Female; Humans; Intestinal Absorption; K

1991
[Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49 Suppl

    Topics: Acetates; Acetic Acid; Allantoin; Aluminum Hydroxide; Bicarbonates; Chronic Kidney Disease-Mineral a

1991
Acute effects of calcium carbonate and citrate on secondary hyperparathyroidism in chronic renal failure.
    American journal of nephrology, 1991, Volume: 11, Issue:6

    Topics: Calcium; Calcium Carbonate; Citrates; Citric Acid; Female; Gastric Acidity Determination; Humans; Hy

1991
Citric acid in calcium effervescent tablets may favour aluminium intoxication.
    Nephron, 1991, Volume: 59, Issue:2

    Topics: Aluminum; Aluminum Hydroxide; Calcium; Citrates; Citric Acid; Drug Interactions; Humans; Intestinal

1991
Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1990, Volume: 31, Issue:1

    Topics: Aged; Aluminum; Citrates; Citric Acid; Deferoxamine; Drug Interactions; Gallium Radioisotopes; Human

1990
Effects of oral base therapy on serum ionized calcium, phosphorus and parathyroid hormone in chronic hemodialysis patients.
    The International journal of artificial organs, 1989, Volume: 12, Issue:12

    Topics: Acidosis; Antacids; Bicarbonates; Calcium; Citrates; Citric Acid; Female; Humans; Kidney Failure, Ch

1989
Acute aluminemic encephalopathy in chronic renal failure: the citrate factor.
    The International journal of artificial organs, 1989, Volume: 12, Issue:12

    Topics: Aluminum; Aluminum Hydroxide; Brain Diseases; Citrates; Citric Acid; Drug Interactions; Humans; Inte

1989
Hyperaluminaemia associated with oral citrate and aluminium hydroxide.
    Human toxicology, 1989, Volume: 8, Issue:1

    Topics: Administration, Oral; Aluminum; Aluminum Hydroxide; Citrates; Citric Acid; Drug Interactions; Female

1989
Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.
    The Journal of clinical investigation, 1989, Volume: 83, Issue:1

    Topics: Acetates; Acetic Acid; Adult; Aluminum; Calcium Carbonate; Citrates; Citric Acid; Diet; Humans; Inte

1989
Hyperaluminemia in renal failure: the influence of age and citrate intake.
    Clinical nephrology, 1989, Volume: 31, Issue:1

    Topics: Adult; Age Factors; Aged; Aluminum; Aluminum Hydroxide; Antacids; Brain Diseases; Citrates; Citric A

1989
[Transient extra-osseous increase of isotope activity in the bone scintigram in acetolyt-induced hypercalcemia].
    Wiener klinische Wochenschrift, 1988, Sep-23, Volume: 100, Issue:18

    Topics: Aged; Bone and Bones; Citrates; Citric Acid; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; P

1988
[Aluminum-free phosphate binder in renal failure. Effectiveness and side effects].
    Fortschritte der Medizin, 1988, Apr-30, Volume: 106, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Calcium Carbonate; Calcium Gluconate; Citrates; Citric Acid; Glucona

1988
Severe metabolic alkalosis complicating regional citrate hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1987, Volume: 9, Issue:3

    Topics: Aged; Alkalosis; Citrates; Citric Acid; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Uremi

1987